Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 12/20 | 0.36 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 2/20 | 0.33 |
| ▸ | CA1 | P00915 | 2/20 | 0.33 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | CA9 | Q16790 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18571353 | 1.00 | SCN9A (0.36) | SCN9ASCN5AALDH1A1HPGDTDP1 | |
| SCHEMBL18556123 | 0.82 | SCN9A (0.35) | SCN9ASCN5A | |
| SCHEMBL21800833 | 0.81 | HTT (0.36) | SCN9AALDH1A1 | |
| SCHEMBL24264003 | 0.80 | SCN9A (0.38) | SCN9ASCN5A | |
| SCHEMBL18571143 | 0.80 | SCN7A (0.43) | SCN9ASCN5A | |
| SCHEMBL18556031 | 0.80 | SCN7A (0.43) | SCN9ASCN5A | |
| SCHEMBL18570784 | 0.79 | SCN9A (0.63) | SCN9ASCN5A | |
| SCHEMBL18571442 | 0.79 | SCN9A (0.42) | SCN9ASCN5A | |
| SCHEMBL18571441 | 0.78 | SCN9A (0.63) | SCN9ASCN5A | |
| SCHEMBL21800832 | 0.77 | SCN5A (0.47) | SCN9ASCN5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220055977-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2022-02-24 | — | — | US | disclosed |
| US-11130726-B2 | Therapeutic compounds and methods of use thereof | GENENTECH, INC. (US) | 2021-09-28 | — | — | US | disclosed |
| US-20200087239-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2020-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11130726-B2 | Therapeutic compounds and methods of use thereof | RDX, C3AR1, LPXN | SCN9A 1789/4885SCN5A 1100/4885ALDH1A1 576/4885 |
| US-20200087239-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | RDX, C3AR1, LPXN | SCN9A 1789/4885SCN5A 1100/4885ALDH1A1 576/4885 |
| US-20220055977-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | REN, RDX, MC2R | SCN9A 2486/4885SCN5A 1051/4885ALDH1A1 788/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.